Answer
Yes. Selected products are licensed for superficial bladder cancer, carcinoma in situ and prevention of recurrence after resection.
Sources for this answer
- PHARMORUBICIN — Current selected SmPCemc · Summary of Product Characteristics
- Epirubicin hydrochloride 2 mg/ml solution for injection — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.